Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation. | ACS Chem Biol | 2025 | 39753207 | PubTator, text mining | PubMed |
| An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB. | Drug Dev Res | 2025 | 39749681 | PubTator, text mining | PubMed |
| Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer. | J Med Chem | 2025 | 39746330 | PubTator, text mining | PubMed |
| Investigating protein degradability through site-specific ubiquitin ligase recruitment. | RSC Chem Biol | 2025 | 39711601 | PubTator, text mining | PubMed |
| The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel. | Biochem Pharmacol | 2025 | 39709037 | PubTator, text mining | PubMed |
| Covalent Proximity Inducers. | Chem Rev | 2025 | 39692621 | PubTator, text mining | PubMed |
| Redirecting E3 ubiquitin ligases for targeted protein degradation with heterologous recognition domains. | J Biol Chem | 2025 | 39675716 | PubTator, text mining | PubMed |
| Immunocompetent mouse models of multiple myeloma. | Semin Hematol | 2025 | 39674742 | PubTator, text mining | PubMed |
| Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. | Mol Cancer Ther | 2025 | 39670468 | PubTator, text mining | PubMed |
| A split intein and split luciferase-coupled system for detecting protein-protein interactions. | Mol Syst Biol | 2025 | 39668253 | PubTator, text mining | PubMed |
| The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma. | Blood | 2025 | 39652772 | PubTator, text mining | PubMed |
| An engineered cereblon optimized for high-throughput screening and molecular glue discovery. | Cell Chem Biol | 2025 | 39610248 | PubTator, text mining | PubMed |
| Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies. | Bioorg Chem | 2025 | 39591691 | PubTator, text mining | PubMed |
| Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. | Haematologica | 2025 | 39569422 | PubTator, text mining | PubMed |
| Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2. | Eur J Med Chem | 2025 | 39520729 | PubTator, text mining | PubMed |
| Next steps for targeted protein degradation. | Cell Chem Biol | 2025 | 39500325 | PubTator, text mining | PubMed |
| Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial. | J Am Acad Dermatol | 2025 | 39461504 | PubTator, text mining | PubMed |
| PROTACs in platelets: emerging antithrombotic strategies and future perspectives. | Curr Opin Hematol | 2025 | 39446364 | PubTator, text mining | PubMed |
| Dynamic Detection of the E3-PROTAC-Target Protein Ternary Complex In Vitro and In Vivo via Bimolecular Fluorescence Complementation. | ACS Omega | 2024 | 39713624 | PubTator, text mining | PubMed |
| Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide. | Dent Med Probl | 2024 | 39704419 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=17